France
· Delayed Price · Currency is EUR TheraVet Statistics
Total Valuation
TheraVet has a market cap or net worth of EUR 292,672. The enterprise value is 1.03 million.
| Market Cap | 292,672 |
| Enterprise Value | 1.03M |
Important Dates
The last earnings date was Thursday, April 10, 2025.
| Earnings Date | Apr 10, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TheraVet has 3.57 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 3.57M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.08% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.32 |
| PB Ratio | 0.06 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.68 |
| EV / Sales | 1.12 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.39, with a Debt / Equity ratio of 0.28.
| Current Ratio | 1.39 |
| Quick Ratio | 1.24 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -72.50 |
Financial Efficiency
Return on equity (ROE) is -25.49% and return on invested capital (ROIC) is -16.27%.
| Return on Equity (ROE) | -25.49% |
| Return on Assets (ROA) | -15.43% |
| Return on Invested Capital (ROIC) | -16.27% |
| Return on Capital Employed (ROCE) | -29.72% |
| Revenue Per Employee | 153,053 |
| Profits Per Employee | -252,366 |
| Employee Count | 7 |
| Asset Turnover | 0.12 |
| Inventory Turnover | 12.32 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -89.59% in the last 52 weeks. The beta is -0.50, so TheraVet's price volatility has been lower than the market average.
| Beta (5Y) | -0.50 |
| 52-Week Price Change | -89.59% |
| 50-Day Moving Average | 0.08 |
| 200-Day Moving Average | 0.13 |
| Relative Strength Index (RSI) | 29.02 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, TheraVet had revenue of EUR 918,316 and -1.51 million in losses. Loss per share was -0.47.
| Revenue | 918,316 |
| Gross Profit | -647,825 |
| Operating Income | -1.86M |
| Pretax Income | -1.56M |
| Net Income | -1.51M |
| EBITDA | -1.96M |
| EBIT | -1.86M |
| Loss Per Share | -0.47 |
Balance Sheet
The company has 713,562 in cash and 1.45 million in debt, giving a net cash position of -740,356 or -0.21 per share.
| Cash & Cash Equivalents | 713,562 |
| Total Debt | 1.45M |
| Net Cash | -740,356 |
| Net Cash Per Share | -0.21 |
| Equity (Book Value) | 5.28M |
| Book Value Per Share | 1.64 |
| Working Capital | 342,762 |
Cash Flow
| Operating Cash Flow | -503,926 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is -70.54%, with operating and profit margins of -203.03% and -164.89%.
| Gross Margin | -70.54% |
| Operating Margin | -203.03% |
| Pretax Margin | -169.87% |
| Profit Margin | -164.89% |
| EBITDA Margin | -213.16% |
| EBIT Margin | -203.03% |
| FCF Margin | n/a |
Dividends & Yields
TheraVet does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -517.37% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TheraVet has an Altman Z-Score of -0.78. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.78 |
| Piotroski F-Score | n/a |